eFFECTOR Therapeutics Overview
- Founded
- 2012
- Status
- Public
- Employees
- 22
- Stock Symbol
- EFTR
- Investments
- 1
- Share Price
- $4.17
- (As of Monday Closing)
eFFECTOR Therapeutics General Information
Description
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs). Its product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT, and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 11120 Roselle Street
- Suite A
- San Diego, CA 92121
- United States
+1 (858) 000-0000
eFFECTOR Therapeutics Timeline
eFFECTOR Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.17 | $4.45 | $4.02 - $40.42 | $182M | 40.8M | 88.5K |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
eFFECTOR Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore eFFECTOR Therapeutics‘s full profile, request access.
Request a free trialeFFECTOR Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore eFFECTOR Therapeutics‘s full profile, request access.
Request a free trialeFFECTOR Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new c
Drug Discovery
San Diego, CA
22
As of 2021
00000
00000000
00000
000 0000
liqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea comm
0000 000000000
Wilmington, DE
00
As of 0000
000.00
00000000000
000.00
00000 00
ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000000000000
Pittsburgh, PA
0
As of 0000
00.000
0000000000 0
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialeFFECTOR Therapeutics Competitors (82)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AUM Biosciences | Venture Capital-Backed | Wilmington, DE | 00 | 000.00 | 00000000000 | 000.00 |
| 00000 0000 0000 | Venture Capital-Backed | Pittsburgh, PA | 0 | 00.000 | 0000000000 0 | 00.000 |
| 0000000 0000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
| 0000000 | Corporation | London, Canada | 00 | 000.00 | 00000000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Berkeley, CA | 00 | 00000 | 00000000 | 00000 |
eFFECTOR Therapeutics Patents
eFFECTOR Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210299111-A1 | Eif4a inhibitor combinations | Pending | 24-Mar-2020 | 000000000 | |
| CA-3085255-A1 | Eif4e-inhibiting compounds and methods | Pending | 02-Jul-2019 | 0000000000 | |
| AU-2019366947-A1 | Crystalline forms of mnk inhibitors | Pending | 24-Oct-2018 | 0000000000 | |
| US-20200131179-A1 | Crystalline forms of mnk inhibitors | Granted | 24-Oct-2018 | 0000000000 | |
| US-11130757-B2 | Crystalline forms of mnk inhibitors | Active | 24-Oct-2018 | C07D471/04 | 0 |
eFFECTOR Therapeutics Executive Team (13)
eFFECTOR Therapeutics Board Members (17)
| Name | Representing | Role | Since |
|---|---|---|---|
| Barbara Klencke MD | Self | Board Member | 000 0000 |
| Brian Gallagher Ph.D | Self | Chairman & Board Member | 000 0000 |
| Denis Patrick Ph.D | Pfizer Ventures | Board Member | 000 0000 |
| John Smither | Self | Board Member | 000 0000 |
| Laurence Lasky Ph.D | US Venture Partners | Board Member | 000 0000 |
eFFECTOR Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialeFFECTOR Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore eFFECTOR Therapeutics‘s full profile, request access.
Request a free trialeFFECTOR Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 0000 0 | 26-Aug-2021 | 0000000000 | Special Purpose Acquisition Company (SPAC) | 0000000 0 |